IMMUTEP LIMITED (IMM)
Share Price Analysis and Chart

07/05/2025

1

Speculative Buy

$0.70

191.67%

Bell Potter observes Immutep reported highly encouraging survival data from its Phase 2 trial in head and neck cancer patients.

The trial showed a median overall survival of 17.6 months for efti plus pembrolizuma, significantly exceeding the circa 11 months seen with current chemo-based standards, explain the analysts.

While the data is promising, limitations include the small 31-patient dataset, absence of a control arm, and pending results from other patient cohorts, highlights the broker.

Bell Potter maintains a Speculative Buy rating and a target price of $0.70.

FORECAST
Bell Potter forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -4.20 cents.
Bell Potter forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -5.50 cents.

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

21/07/2025

1

Overweight

$1.20

400.00%

Wilsons notes recent updates from Immutep's Insight-003 and Tacti-003 trials reinforce the potential of Efti in cancer treatment.

In the background, the company has also been working on IMP761, a first-in-class LAG-3 that works by suppressing immune activity rather than stimulating T cells.

The broker believes IMP761 has the potential to treat autoimmune diseases such as rheumatoid arthritis and inflammatory bowel disease.

A phase 1 trial in healthy volunteers is underway, and the broker has incorporated the antibody's potential into its forecasts.

Overweight. Target rises to $1.20 from $1.05.

FORECAST
Wilsons forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -4.20 cents.
Wilsons forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -5.70 cents.